Pharma Stocks Outlook for the week - 28 .08.2017 to 01.09.2017
Pharma Stocks Outlook for the week - 28 .08.2017 to 01.09.2017
( www.rupeedesk.in )
The Value buying in pharmaceutical stocks seen today is expected to continue next week, despite the fact that many market participants have a bleak outlook for the sector for the current and coming financial years. The Nifty Pharma index is seen continuing its rebound for the third week, after hitting an over-three-year low of 8314.50 points earlier this month. While traders may view the sector positively, we advise investors to be cautious over the coming year. Except for Aurobindo and Cipla commentary, most management commentaries indicate incessant pricing pressure in the US and domestic disruption (in Apr-Sep) due to GST rollout. Prospects of a recovery in Oct-Mar and 2018-19 (Apr-Mar) look bleak due to lack of regulatory-compliant facilities, appreciation of the rupee against the dollar and regulatory changes proposed for domestic markets. Right now, there are no positive triggers for the sector. There are too many headwinds, such as pricing pressure in the US and uncertainty over domestic policies for pharmaceutical companies.
Source : Cogencis Information Services Ltd.
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Free Commodity Tips : Join our Whatsapp No : 9094047040
Pharma Stocks Outlook for the week - 28 .08.2017 to 01.09.2017
( www.rupeedesk.in )
The Value buying in pharmaceutical stocks seen today is expected to continue next week, despite the fact that many market participants have a bleak outlook for the sector for the current and coming financial years. The Nifty Pharma index is seen continuing its rebound for the third week, after hitting an over-three-year low of 8314.50 points earlier this month. While traders may view the sector positively, we advise investors to be cautious over the coming year. Except for Aurobindo and Cipla commentary, most management commentaries indicate incessant pricing pressure in the US and domestic disruption (in Apr-Sep) due to GST rollout. Prospects of a recovery in Oct-Mar and 2018-19 (Apr-Mar) look bleak due to lack of regulatory-compliant facilities, appreciation of the rupee against the dollar and regulatory changes proposed for domestic markets. Right now, there are no positive triggers for the sector. There are too many headwinds, such as pricing pressure in the US and uncertainty over domestic policies for pharmaceutical companies.
Source : Cogencis Information Services Ltd.
